{"id":"https://openalex.org/W7204846519","doi":"https://doi.org/10.1158/2767-9764.33395327","title":"Figure 3 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer","display_name":"Figure 3 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer","publication_year":2026,"publication_date":"2026-08-31","ids":{"openalex":"https://openalex.org/W7204846519","doi":"https://doi.org/10.1158/2767-9764.33395327"},"language":"en","primary_location":{"id":"doi:10.1158/2767-9764.33395327","doi":"https://doi.org/10.1158/2767-9764.33395327","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2767-9764.33395327","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/2767-9764.33395327","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5055547973","display_name":"Anne B. Richardson","orcid":"https://orcid.org/0000-0001-9846-7706","observed_orcids":["https://orcid.org/0000-0001-9846-7706"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Annie Blair Richardson","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9846-7706","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5148796521","display_name":"Payel Chatterjee","orcid":"https://orcid.org/0009-0004-7474-9740","observed_orcids":["https://orcid.org/0009-0004-7474-9740"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Payel Chatterjee","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0004-7474-9740","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076719905","display_name":"Rachele Rosati","orcid":"https://orcid.org/0009-0005-6731-3954","observed_orcids":["https://orcid.org/0009-0005-6731-3954"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rachele Rosati","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0005-6731-3954","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054905861","display_name":"Alex C. Rajewski","orcid":"https://orcid.org/0000-0003-3475-1999","observed_orcids":["https://orcid.org/0000-0003-3475-1999"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alex Rajewski","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3475-1999","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113934312","display_name":"Robert L. Diaz","orcid":"https://orcid.org/0009-0005-7880-0758","observed_orcids":["https://orcid.org/0009-0005-7880-0758"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert L. Diaz","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0005-7880-0758","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053334479","display_name":"Lauren R. Appleyard","orcid":"https://orcid.org/0009-0007-0492-3063","observed_orcids":["https://orcid.org/0009-0007-0492-3063"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lauren R. Appleyard","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0007-0492-3063","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078025339","display_name":"Shalini E. Pereira","orcid":"https://orcid.org/0009-0008-8610-6645","observed_orcids":["https://orcid.org/0009-0008-8610-6645"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shalini Pereira","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0008-8610-6645","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080158021","display_name":"Brady M. Bernard","orcid":"https://orcid.org/0000-0003-2118-9829","observed_orcids":["https://orcid.org/0000-0003-2118-9829"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Brady Bernard","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-2118-9829","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054771911","display_name":"Milind M. Javle","orcid":"https://orcid.org/0000-0001-9158-0941","observed_orcids":["https://orcid.org/0000-0001-9158-0941"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Milind M. Javle","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9158-0941","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073989587","display_name":"Gentry Teng King","orcid":"https://orcid.org/0000-0002-7525-8802","observed_orcids":["https://orcid.org/0000-0002-7525-8802"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gentry G. King","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-7525-8802","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039939671","display_name":"Adam Diehl","orcid":"https://orcid.org/0000-0003-4984-8128","observed_orcids":["https://orcid.org/0000-0003-4984-8128"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Adam Diehl","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-4984-8128","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113286006","display_name":"William Proctor Harris","orcid":"https://orcid.org/0000-0002-3977-4017","observed_orcids":["https://orcid.org/0000-0002-3977-4017"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"William Proctor Harris","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-3977-4017","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088856020","display_name":"Sameek Roychowdhury","orcid":"https://orcid.org/0000-0002-8297-3038","observed_orcids":["https://orcid.org/0000-0002-8297-3038"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sameek Roychowdhury","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8297-3038","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112265164","display_name":"Christopher J. Kemp","orcid":"https://orcid.org/0000-0001-7238-8452","observed_orcids":["https://orcid.org/0000-0001-7238-8452"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christopher J. Kemp","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7238-8452","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5072279288","display_name":"Carla Grandori","orcid":"https://orcid.org/0009-0009-4682-9731","observed_orcids":["https://orcid.org/0009-0009-4682-9731","https://orcid.org/0000-0001-9109-410X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Carla Grandori","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0009-4682-9731","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11364","display_name":"Cholangiocarcinoma and Gallbladder Cancer Studies","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11364","display_name":"Cholangiocarcinoma and Gallbladder Cancer Studies","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/biliary-tract-cancer","display_name":"biliary tract cancer","score":0.9800000190734863},{"id":"https://openalex.org/keywords/pharmacotyping","display_name":"pharmacotyping","score":0.8999999761581421},{"id":"https://openalex.org/keywords/fgfr-inhibitors","display_name":"FGFR inhibitors","score":0.7940000295639038},{"id":"https://openalex.org/keywords/braf-inhibitors","display_name":"BRAF inhibitors","score":0.9789999723434448},{"id":"https://openalex.org/keywords/mek-inhibitors","display_name":"MEK inhibitors","score":0.9990000128746033},{"id":"https://openalex.org/keywords/pi3k-inhibitors","display_name":"PI3K inhibitors","score":0.8759999871253967},{"id":"https://openalex.org/keywords/egfr-inhibitors","display_name":"EGFR inhibitors","score":0.9710000157356262},{"id":"https://openalex.org/keywords/drug-response","display_name":"drug response","score":0.5339999794960022},{"id":"https://openalex.org/keywords/genetic-biomarkers","display_name":"genetic biomarkers","score":0.9190000295639038},{"id":"https://openalex.org/keywords/personalized-treatment","display_name":"personalized treatment","score":0.4970000088214874},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.38999998569488525}],"concepts":[{"id":"https://openalex.org/C2777329042","wikidata":"https://www.wikidata.org/wiki/Q420323","display_name":"Lapatinib","level":5,"score":0.7990000247955322},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7459999918937683},{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.6908000111579895},{"id":"https://openalex.org/C26291073","wikidata":"https://www.wikidata.org/wiki/Q310484","display_name":"Ex vivo","level":3,"score":0.63919997215271},{"id":"https://openalex.org/C2779536868","wikidata":"https://www.wikidata.org/wiki/Q419940","display_name":"Dasatinib","level":4,"score":0.620199978351593},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.5834000110626221},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.541700005531311},{"id":"https://openalex.org/C2777506169","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"EGFR inhibitors","level":4,"score":0.5113999843597412},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.4341000020503998},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.4253999888896942},{"id":"https://openalex.org/C115456853","wikidata":"https://www.wikidata.org/wiki/Q17917132","display_name":"ERBB3","level":4,"score":0.4221000075340271},{"id":"https://openalex.org/C2776087337","wikidata":"https://www.wikidata.org/wiki/Q7448840","display_name":"Selumetinib","level":5,"score":0.4221000075340271},{"id":"https://openalex.org/C2780333294","wikidata":"https://www.wikidata.org/wiki/Q7914515","display_name":"Vandetanib","level":4,"score":0.42179998755455017},{"id":"https://openalex.org/C1167327","wikidata":"https://www.wikidata.org/wiki/Q14884140","display_name":"HRAS","level":5,"score":0.42149999737739563},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3955000042915344},{"id":"https://openalex.org/C2779490328","wikidata":"https://www.wikidata.org/wiki/Q417542","display_name":"Sunitinib","level":3,"score":0.39070001244544983},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.3873000144958496},{"id":"https://openalex.org/C2781064419","wikidata":"https://www.wikidata.org/wiki/Q795057","display_name":"Cabozantinib","level":3,"score":0.35359999537467957},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.35100001096725464},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.3443000018596649},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.34310001134872437},{"id":"https://openalex.org/C2779251935","wikidata":"https://www.wikidata.org/wiki/Q5385089","display_name":"ErbB","level":3,"score":0.3359000086784363},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.32749998569488525},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3273000121116638},{"id":"https://openalex.org/C31695470","wikidata":"https://www.wikidata.org/wiki/Q11293125","display_name":"Organoid","level":2,"score":0.3190000057220459},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.3188000023365021},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.3052000105381012},{"id":"https://openalex.org/C2778468042","wikidata":"https://www.wikidata.org/wiki/Q273976","display_name":"Blockade","level":3,"score":0.30329999327659607},{"id":"https://openalex.org/C82867764","wikidata":"https://www.wikidata.org/wiki/Q24780051","display_name":"Fibroblast growth factor receptor","level":4,"score":0.289900004863739},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.28519999980926514},{"id":"https://openalex.org/C2780846426","wikidata":"https://www.wikidata.org/wiki/Q1138188","display_name":"Cowden syndrome","level":5,"score":0.28369998931884766},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.26669999957084656},{"id":"https://openalex.org/C2780381907","wikidata":"https://www.wikidata.org/wiki/Q198728","display_name":"Ponatinib","level":5,"score":0.2635999917984009},{"id":"https://openalex.org/C108636557","wikidata":"https://www.wikidata.org/wiki/Q21109354","display_name":"Proto-oncogene tyrosine-protein kinase Src","level":3,"score":0.26159998774528503},{"id":"https://openalex.org/C2777413986","wikidata":"https://www.wikidata.org/wiki/Q412327","display_name":"Nilotinib","level":4,"score":0.26159998774528503},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.2614000141620636},{"id":"https://openalex.org/C200786668","wikidata":"https://www.wikidata.org/wiki/Q3498029","display_name":"Invadopodia","level":4,"score":0.2556000053882599},{"id":"https://openalex.org/C183713625","wikidata":"https://www.wikidata.org/wiki/Q5282002","display_name":"Discovery and development of mTOR inhibitors","level":4,"score":0.25459998846054077}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/2767-9764.33395327","doi":"https://doi.org/10.1158/2767-9764.33395327","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2767-9764.33395327","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/2767-9764.33395327","doi":"https://doi.org/10.1158/2767-9764.33395327","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2767-9764.33395327","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7202126691","https://openalex.org/W7204836925","https://openalex.org/W4406869970","https://openalex.org/W7204815506","https://openalex.org/W7204763602","https://openalex.org/W7204819033","https://openalex.org/W7204809751","https://openalex.org/W7204777687","https://openalex.org/W4282970493","https://openalex.org/W4392698941"],"abstract_inverted_index":{"Concordance":[0],"of":[1,11,68,104,134,177],"ex":[2],"vivo":[3],"drug":[4],"response":[5],"and":[6,20,32,62,79,86,88,98,120,128,146,148,153,160],"genetic":[7],"biomarkers.":[8],"A,":[9],"Heatmap":[10,67,103,133],"responses":[12,69,105,135],"to":[13,55,70,106,136,166],"the":[14,71,75,81,89,107,116,121,137,149,172],"FDA-approved":[15],"FGFR":[16,26,49,56],"inhibitors":[17,27,77,83,109,139,151],"futibatinib,":[18],"infigratinib,":[19],"pemigatinib,":[21],"as":[22,24,38],"well":[23],"other":[25],"derazantinib,":[28],"AZD4547,":[29],"dovitinib,":[30],"lucitanib,":[31],"erdafitinib.":[33],"Dasatinib":[34],"was":[35,181],"included":[36],"because,":[37],"shown":[39],"here,":[40],"sensitivity":[41],"has":[42],"been":[43],"detected":[44],"in":[45,59,94,126,156],"several":[46],"tumors":[47],"with":[48],"alterations":[50],"that":[51,171],"are":[52,64,100,130,162],"clinically":[53],"resistant":[54],"inhibitors.":[57],"Alterations":[58,93,125,155],"FGFR1,":[60],"FGFR2,":[61],"FGFR3":[63],"annotated.":[65,101,131,163],"B,":[66],"HRAS":[72],"inhibitor":[73,91,118,123],"tipifarnib;":[74],"BRAF":[76],"vemurafenib":[78],"dabrafenib;":[80],"MEK":[82],"cobimetinib,":[84],"trametinib,":[85],"binimetinib;":[87],"ERK":[90],"ulixertinib.":[92],"KRAS,":[95],"NRAS,":[96],"BRAF,":[97],"MEK1":[99],"C,":[102],"PI3K":[108],"alpelisib,":[110],"AZD6482,":[111],"buparlisib,":[112],"idelalisib,":[113],"NVP-BGT226,":[114],"taselisib,":[115],"PI3K/mTOR":[117],"dactolisib,":[119],"mTOR":[122],"everolimus.":[124],"PIK3CA":[127],"PIK3CB":[129],"D,":[132],"EGFR":[138],"afatinib,":[140],"dacomitinib,":[141],"erlotinib,":[142],"gefitinib,":[143],"osimertinib,":[144],"poziotinib,":[145],"vandetanib":[147],"ERBB2":[150],"lapatinib":[152],"neratinib.":[154],"EGFR,":[157],"ERBB2,":[158],"ERBB3,":[159],"ERBB4":[161],"Asterisks":[164],"next":[165],"a":[167,175],"patient":[168],"number":[169],"signify":[170],"screen":[173],"failed":[174],"measure":[176],"quality":[178],"control":[179],"but":[180],"still":[182],"evaluable.":[183]},"counts_by_year":[],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2026-09-01T00:00:00"}